Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells $145,174.37 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 7,373 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total transaction of $145,174.37. Following the completion of the transaction, the insider owned 144,985 shares of the company’s stock, valued at $2,854,754.65. This represents a 4.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Wednesday, November 19th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $25.00, for a total value of $250,000.00.

Urogen Pharma Stock Performance

Urogen Pharma stock opened at $21.35 on Friday. The company has a market capitalization of $999.39 million, a P/E ratio of -6.17 and a beta of 1.32. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $30.00. The stock has a 50-day simple moving average of $21.96 and a 200-day simple moving average of $20.64.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.03. The firm had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. As a group, analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP acquired a new position in Urogen Pharma during the third quarter worth $84,111,000. Soleus Capital Management L.P. acquired a new stake in Urogen Pharma in the second quarter valued at $29,934,000. SG Americas Securities LLC increased its position in shares of Urogen Pharma by 607.1% in the second quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock valued at $15,742,000 after buying an additional 986,567 shares in the last quarter. TCG Crossover Management LLC acquired a new position in shares of Urogen Pharma during the 3rd quarter worth $14,311,000. Finally, Voloridge Investment Management LLC purchased a new stake in shares of Urogen Pharma in the 3rd quarter worth about $13,715,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Analysts Set New Price Targets

URGN has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Urogen Pharma in a research note on Monday, October 27th. D. Boral Capital reiterated a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.